2025年1至6月份，国发股份的营业收入构成为：医药流通占比62.04%，DNA耗材及检测服务占比 22.16%，医药制造占比8.29%，司法鉴定占比6.22%，其他业务占比1.04%。 截至发稿，国发股份市值为33亿元。 每经AI快讯，国发股份（SH 600538，收盘价：6.35元）12月25日晚间发布公告称，公司第十一届第二 十一次董事会会议于2025年12月25日以现场及通讯表决方式召开。会议审议了《关于选举第十一届董事 会董事长的议案》等文件。 每经头条（nbdtoutiao）——微信聊天遭老板监视，杀毒软件"失明"，员工隐私被系统性采集！软件商 公开售卖"监控神器"，称已服务多家企业 （记者 王晓波） ...

Group 1 - The major shareholder of Guofa Co., Ltd. (国发股份) has had a portion of shares frozen by the Nanning Qingxiu District People's Court, affecting approximately 39.69 million shares held by Zhu Rongjuan, 3.47 million shares held by Peng Tao, and 690,000 shares held by Guangxi Guofa Investment Group [1] - As of the announcement date, Guofa Co., Ltd. has a market capitalization of 3.1 billion yuan [2] - For the first half of 2025, the revenue composition of Guofa Co., Ltd. is as follows: pharmaceutical distribution accounts for 62.04%, DNA consumables and testing services account for 22.16%, pharmaceutical manufacturing accounts for 8.29%, judicial identification accounts for 6.22%, and other businesses account for 1.04% [1]

Group 1 - The major shareholder Zhu Rongjuan and her associate Peng Tao of Guofang Co., Ltd. are facing a financial dispute with Guangxi Beibu Gulf Bank, leading to the freezing of approximately 38.56 million and 3.37 million shares respectively as of November 5, 2025 [1] - As of the announcement date, Zhu Rongjuan has a total of about 39.69 million shares frozen, while Peng Tao has around 3.47 million shares frozen, and Guangxi Guofang Investment Group has about 180,000 shares frozen [1] - The company's market capitalization is currently valued at 3 billion yuan [1] Group 2 - For the first half of 2025, Guofang Co., Ltd.'s revenue composition is as follows: pharmaceutical distribution accounts for 62.04%, DNA consumables and testing services 22.16%, pharmaceutical manufacturing 8.29%, judicial identification 6.22%, and other businesses 1.04% [1]